source
- Roche’s divarasib shows survival benefit over Amgen and BMS drugs in KRAS G12C lung cancer trialRoche reported that its experimental KRAS G12C inhibitor divarasib extended overall survival and progression‑free survival in a Phase 3 head‑to‑head study against Amgen’s Lumakra and Bristol Myers…
- FDA grants first clearance for patient-facing LLM diabetes app, marking historic step for AI in medical softwareUpDoc's diabetes management app received FDA clearance, the first for software that uses patient-facing large language models. The app is designed to help patients follow treatment plans set by th…